182 related articles for article (PubMed ID: 38369808)
1. Accumulation of circulating myeloid-derived suppressor cell subsets: predicting poor clinical efficacy and prognosis through T cell suppression in non-Hodgkin's lymphoma.
Pu LF; Li MM; Feng XJ; Zhang T; Hu LH; Zheng HM; Charwudzi A; Ding YY; Liu J; Liu ZL; Xiong SD
J Leukoc Biol; 2024 May; 115(6):1094-1107. PubMed ID: 38369808
[TBL] [Abstract][Full Text] [Related]
2. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients.
Marini O; Spina C; Mimiola E; Cassaro A; Malerba G; Todeschini G; Perbellini O; Scupoli M; Carli G; Facchinelli D; Cassatella M; Scapini P; Tecchio C
Oncotarget; 2016 May; 7(19):27676-88. PubMed ID: 27050283
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy.
Foureau DM; Guo F; Steuerwald NM; Druhan LJ; Avalos BR; Copelan E; Sun D; Hu B; Moyo T; Jacobs R; Park S; Ghosh N
Exp Hematol; 2024 Jan; 129():104125. PubMed ID: 38743005
[TBL] [Abstract][Full Text] [Related]
4. Elevated circulating myeloid-derived suppressor cells associated with poor prognosis in B-cell non-Hodgkin's lymphoma patients.
Wang Y; Wang J; Zhu F; Wang H; Yi L; Huang K; Zhai Z
Immun Inflamm Dis; 2022 May; 10(5):e616. PubMed ID: 35478441
[TBL] [Abstract][Full Text] [Related]
5. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
[TBL] [Abstract][Full Text] [Related]
6. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
[TBL] [Abstract][Full Text] [Related]
7. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.
Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S
Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893
[No Abstract] [Full Text] [Related]
8. Expansion and activation of monocytic-myeloid-derived suppressor cell via STAT3/arginase-I signaling in patients with ankylosing spondylitis.
Liu YF; Zhuang KH; Chen B; Li PW; Zhou X; Jiang H; Zhong LM; Liu FB
Arthritis Res Ther; 2018 Aug; 20(1):168. PubMed ID: 30075733
[TBL] [Abstract][Full Text] [Related]
9. Decidua-derived granulocyte macrophage colony-stimulating factor induces polymorphonuclear myeloid-derived suppressor cells from circulating CD15+ neutrophils.
Li C; Chen C; Kang X; Zhang X; Sun S; Guo F; Wang Q; Kou X; Bai W; Zhao A
Hum Reprod; 2020 Dec; 35(12):2677-2691. PubMed ID: 33067638
[TBL] [Abstract][Full Text] [Related]
10. Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer.
Barrera L; Montes-Servín E; Hernandez-Martinez JM; Orozco-Morales M; Montes-Servín E; Michel-Tello D; Morales-Flores RA; Flores-Estrada D; Arrieta O
Cancer Immunol Immunother; 2018 Sep; 67(9):1393-1406. PubMed ID: 29974189
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma.
Sato Y; Shimizu K; Shinga J; Hidaka M; Kawano F; Kakimi K; Yamasaki S; Asakura M; Fujii SI
Oncoimmunology; 2015 Mar; 4(3):e995541. PubMed ID: 25949922
[TBL] [Abstract][Full Text] [Related]
12. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.
Cole KE; Ly QP; Hollingsworth MA; Cox JL; Padussis JC; Foster JM; Vargas LM; Talmadge JE
Cell Immunol; 2021 May; 363():104317. PubMed ID: 33714729
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL.
Ferrer G; Jung B; Chiu PY; Aslam R; Palacios F; Mazzarello AN; Vergani S; Bagnara D; Chen SS; Yancopoulos S; Xochelli A; Yan XJ; Burger JA; Barrientos JC; Kolitz JE; Allen SL; Stamatopoulos K; Rai KR; Sherry B; Chiorazzi N
Leukemia; 2021 Nov; 35(11):3163-3175. PubMed ID: 33935280
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
[TBL] [Abstract][Full Text] [Related]
15. Arginase 1
Neri D; Carevic-Neri M; Brück J; Holstein J; Schäfer I; Solimani F; Handgretinger R; Hartl D; Ghoreschi K
Exp Dermatol; 2021 Jun; 30(6):782-791. PubMed ID: 33528891
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-derived suppressor cells increase and inhibit donor-reactive T cell responses to graft intestinal epithelium in intestinal transplant patients.
Okano S; Abu-Elmagd K; Kish DD; Keslar K; Baldwin WM; Fairchild RL; Fujiki M; Khanna A; Osman M; Costa G; Fung J; Miller C; Kayashima H; Hashimoto K
Am J Transplant; 2018 Oct; 18(10):2544-2558. PubMed ID: 29509288
[TBL] [Abstract][Full Text] [Related]
17. Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma.
Zhong LM; Liu ZG; Zhou X; Song SH; Weng GY; Wen Y; Liu FB; Cao DL; Liu YF
Oral Oncol; 2019 Aug; 95():157-163. PubMed ID: 31345384
[TBL] [Abstract][Full Text] [Related]
18. High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP.
Dhar S; Chakravarti M; Ganguly N; Saha A; Dasgupta S; Bera S; Sarkar A; Roy K; Das J; Bhuniya A; Ghosh S; Sarkar M; Hajra S; Banerjee S; Pal C; Saha B; Mukherjee KK; Baral R; Bose A
Front Immunol; 2023; 14():1303959. PubMed ID: 38304256
[TBL] [Abstract][Full Text] [Related]
19. Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer.
Okła K; Czerwonka A; Wawruszak A; Bobiński M; Bilska M; Tarkowski R; Bednarek W; Wertel I; Kotarski J
Front Immunol; 2019; 10():691. PubMed ID: 31001284
[TBL] [Abstract][Full Text] [Related]
20. Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis.
Ruan WS; Feng MX; Xu J; Xu YG; Song CY; Lin LY; Li L; Lu YQ
Front Immunol; 2020; 11():1299. PubMed ID: 32719675
[No Abstract] [Full Text] [Related]
[Next] [New Search]
